Likewise, in mouse models of primary tauopathy, characterized by inclusions of the protein tau in neural cells (Kovacs, 2015), CSF1R inhibitors reduced pathological tau aggregation and subsequent neurodegeneration (Mancuso et al., 2019; Shi et al., 2019). Here, MAPT is linked to tauopathy.